Combination chemotherapies have been a mainstay in the treatment of disseminated
malignancies for almost 60 y, yet even successful regimens fail to cure many patients …

The majority of diseases are associated with alterations in multiple molecular pathways and
complex interactions at the cellular and organ levels. Single-target monotherapies therefore …

Recent tumor sequencing data suggest an urgent need to develop a methodology to directly
address intratumoral heterogeneity in the design of anticancer treatment regimens. We use …

Combinations of therapies are being actively pursued to expand therapeutic options and
deal with cancer's pervasive resistance to treatment. Research efforts to discover effective …

Recent advances in genomic sequencing and omics-based capabilities are uncovering
tremendous therapeutic opportunities and rapidly transforming the field of cancer medicine …

Understanding the molecular mechanisms underlying synergistic, potentiative and
antagonistic effects of drug combinations could facilitate the discovery of novel efficacious …

The effectiveness of most cancer targeted therapies is short-lived. Tumors often develop
resistance that might be overcome with drug combinations. However, the number of possible …

The current clinical application of combination chemotherapy is guided by a historically
successful set of practices that were developed by basic and clinical researchers 50–60 …

Personalized cancer treatments using combinations of drugs with a synergistic effect is
attractive but proves to be highly challenging. Here we present an approach to uncover the …

Combination therapies are superior to monotherapy for many cancers. This advantage was
historically ascribed to the ability of combinations to address tumor heterogeneity, but …